The filing assumes a $5.50 unit price, which would bring net proceeds of about $17.98 million. The financial statements carry a going-concern paragraph, and the accumulated deficit was $38,027,000 at September 30, 2025.
Latest InnoCan Pharma news
We have not published a story on InnoCan Pharma yet. When there is news, it will appear here.
Questions about InnoCan Pharma
Has InnoCan Pharma issued a going-concern warning?
Our latest story on this, dated Mar 16, 2026: "InnoCan Pharma files for US IPO of 3,750,000 units, with NYSE American listing sought". The story links the filing or release it is based on. Read the story.
When did InnoCan Pharma go public?
Our latest story on this, dated Mar 16, 2026: "InnoCan Pharma files for US IPO of 3,750,000 units, with NYSE American listing sought". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of InnoCan Pharma?
InnoCan Pharma Corporation trades under the ticker INNO on CSE.
Where is InnoCan Pharma listed?
InnoCan Pharma Corporation is listed on CSE. Our directory also records these other listings: GETTEX:IP40; LS:A41FTP; LSX:A41FTP; OTC:INNPF.
What is the SEC CIK of InnoCan Pharma?
The SEC Central Index Key (CIK) for InnoCan Pharma Corporation is 1889791. Its filings are on SEC EDGAR.
Which country or territory is InnoCan Pharma listed under?
Our directory records InnoCan Pharma Corporation under Canada.
What does InnoCan Pharma do?
Our directory classifies InnoCan Pharma Corporation as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of InnoCan Pharma?
The ISIN recorded for InnoCan Pharma Corporation is CA45783P5085.
Does aibio.space cover InnoCan Pharma?
aibio.space lists InnoCan Pharma Corporation among 2,820 public biotech companies and publishes its news here as stories appear.
Where is InnoCan Pharma incorporated?
SEC records list its state or country of incorporation as Z4.
What is the latest InnoCan Pharma (INNO) stock news?
Our latest story on InnoCan Pharma, dated Mar 16, 2026: "InnoCan Pharma files for US IPO of 3,750,000 units, with NYSE American listing sought". The filing assumes a $5.50 unit price, which would bring net proceeds of about $17.98 million. The financial statements carry a going-concern paragraph, and the accumulated deficit was $38,027,000 at September 30, 2025. Source.
What is InnoCan Pharma's latest stock offering or financing news?
Our latest financing story, dated Mar 16, 2026: "InnoCan Pharma files for US IPO of 3,750,000 units, with NYSE American listing sought". The filing assumes a $5.50 unit price, which would bring net proceeds of about $17.98 million. The financial statements carry a going-concern paragraph, and the accumulated deficit was $38,027,000 at September 30, 2025. Source.
Who were the underwriters or placement agents on InnoCan Pharma's offering?
From our story: The cover names ThinkEquity as the underwriter. Source.
How long will InnoCan Pharma's cash last?
From our story of Mar 16, 2026: The financial statements carry a going-concern paragraph, and the accumulated deficit was $38,027,000 at September 30, 2025. Source.
Where is InnoCan Pharma headquartered?
SEC records list its business address as 1015, 926 - 5 AVENUE SW, CALGARY, T2P 0N7.
Investor discussion: InnoCan Pharma
Members talk about InnoCan Pharma (INNO). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at InnoCan Pharma, newest first. Each line links the filing it comes from.
Financings
Filed a registration statement for a share offering. SEC Form F-1. Source
Financings
Filed a registration statement for a share offering. SEC Form F-1. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open CSE:INNO on TradingView.
SEC filings and registration
SEC name
INNOCAN PHARMA Corp
CIK
1889791
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
INNPF (OTC)
State or country of incorporation
Z4
Fiscal year ends
December 31
Business address
1015, 926 - 5 AVENUE SW, CALGARY, T2P 0N7
Phone
403-777-1519
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
InnoCan Pharma Corporation is a public biotech or pharmaceutical company listed on CSE under the ticker INNO, recorded under Canada. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio